PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the
effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days
before the start of the conditioning regimen and for 3 consecutive days after autologous
PBSCT for treating oral mucositis in patients with NHL and MM who have received high-dose
conditioning chemotherapy.